JPRN-UMIN000000730已完成3 期
Randomized, double-blind, placebo-controlled study of AMG0001(HGF plasmid) for patients with arteriosclerosis obliterans - Randomized, double-blind, placebo-controlled study of AMG0001(HGF plasmid) for patients with arteriosclerosis obliterans
Anges MG, Inc.0 个研究点目标入组 120 人开始时间: 2007年6月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
Analysis of efficacy was performed in 40 patients with critical limb ischemia (CLI). The primary end point was the improvement of rest pain in patients without ulcers (Rutherford 4) or the reduction of ulcer size in patients with ulcer(s) (Rutherford 5). The overall improvement rate of the primary end point was 70.4% (19/27) in HGF group and 30.8% (4/13) in placebo group, showing a significant difference (P=0.014). In Rutherford 5 patients, HGF achieved a significantly higher improvement rate (100% [11/11]) than placebo (40% [2/5]; P=0.018). HGF plasmid also improved QOL. There were no major safety problems. HGF gene therapy is safe and effective for CLI. Gene Ther. 2010 Sep;17(9):1152-61. Epub 2010 Apr 15.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with a necrotized ulcer and/or an ulcer with exposed tendon or bone 2. Patients in whom alcohol or drug dependence had been noted 90 days or less before informed consent was obtained or who had been treated for it 3. Past history of or complication with cancer 4. Patients with serious cardiac, hepatic, renal, or hematological disease 5. Patients with intercurrent hepatitis B or C, AIDS, or ATL 6. Patients who underwent revascularization or amputation (not necrotomy) 90 days or less before giving informed consent 7. Patients who underwent sympathectomy or sympathetic block 180 days or less before giving informed consent 8. Patients with an invasive infectious disease which is difficult to control with antibiotics 9. Patients with proliferating diabetic retinopathy (untreated or in the middle or late stage of proliferating retinopathy) or neovascularization-type age-related macular degeneration 10. Participation in another clinical trial 90 days or less before giving informed consent 11. Pregnant or breast-feeding women, women with suspected pregnancy, and women who desire to become pregnant during the trial 12. Past history of cell therapy 13. Past history of gene therapy 14. Blood sampling (or donation) of 200 ml or more, 30 days or less before giving informed consent, or 400 ml or more, 90 (120 in the case of women) days or less before giving informed consent
研究者
相似试验
已完成
不适用
A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)Raynaud's PhenomenonRaynaud DiseaseNCT02506062Lawson Health Research Institute21
招募中
2 期
TP03HN106 in Patients With Critical Limb IschemiaCritical Limb IschemiaNCT06482892Talengen Institute of Life Sciences, Shenzhen, P.R. China.15
进行中（未招募）
1 期
Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients With Critical Limb IschemiaCritical Limb IschemiaNCT04661644S.Biomedics Co., Ltd.20
已完成
不适用
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK ArteriesPeripheral Artery DiseaseNCT02554266C. R. Bard371
Unknown
2 期
VADOplex Critical Limb Ischemia StudyPeripheral Artery DiseaseQuality of LifeWound HealingNCT02034539Asklepios Kliniken Hamburg GmbH38